Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
67%(6 trials)

Phase Distribution

Ph phase_3
2
17%
Ph phase_1
5
42%
Ph phase_2
2
17%
Ph not_applicable
1
8%

Phase Distribution

5

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
2(20.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(1)
Other(2)

Detailed Status

Completed9
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 22 (20.0%)
Phase 32 (20.0%)
N/A1 (10.0%)

Trials by Status

completed975%
unknown217%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
withdrawn

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

NCT06227429
completed

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

NCT02320084
completedphase_2

Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

NCT01390077
unknownnot_applicable

Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine

NCT04113772
completedphase_1

Nitisinone for Type 1B Oculocutaneous Albinism

NCT01838655
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06227429

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Withdrawn
NCT02320084

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

Completed
NCT01390077Phase 2

Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

Completed
NCT04113772Not Applicable

Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine

Unknown
NCT01838655Phase 1

Nitisinone for Type 1B Oculocutaneous Albinism

Completed
NCT01916382Phase 3

Suitability of Nitisinone in Alkaptonuria 2

Unknown
NCT02750345Phase 1

Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)

Completed
NCT02750332Phase 1

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

Completed
NCT02750709Phase 1

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

Completed
NCT02323529Phase 3

Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

Completed
NCT01734889Phase 1

Taste and Palatability of Orfadin Suspension

Completed
NCT01828463Phase 2

Dose Response Study of Nitisinone in Alkaptonuria

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12